IQVIA has been named a 'front-runner generative AI leader' for the life sciences industry by the global independent research and analysis firm Everest Group. This recognition was detailed in their recent report, 'AI-deas to Action: Operationalizing Generative AI in Life Sciences.'
IQVIA was the only clinical research organization (CRO) to receive the highest ranking of front-runner in the report, which assessed the value impact of end-to-end generative AI capabilities across 15 selected companies. The company was also noted as the only CRO with a dedicated technology business unit to achieve this designation.
The report specifically highlighted IQVIA's industry leadership in innovative strategic integrations of generative AI capabilities throughout various stages of research and development. This includes its Healthcare-grade AI solutions, which are used to identify nuances in patient journeys for improved clinical trial design, enhance product commercialization strategies, and provide precise market access insights.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.